Episode Details

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce that the company has entered into a Technology Evaluation and License Option Agreement with Swiss Cannabis Selection, a Switzerland-based medical cannabis company focused on the cultivation, development, and production of cannabis and cannabinoid-based products for medical applications. Charleton explained that SCS is collaborating with Schibano Pharma AG, a Swiss phytopharmaceutical company specializing in cannabinoid-derived active pharmaceutical ingredients, medicinal products, and wellness solutions, to evaluate EnWave’s proprietary Radiant Energy Vacuum (REV™) dehydration technology. The evaluation is intended to determine the suitability of the technology across a range of cannabinoid and botanical products as both companies seek innovative solutions that can improve processing efficiency while maintaining product quality. Under the terms of the agreement, SCS and Schibano will conduct a comprehensive assessment of REV™ technology. Upon successful completion of the evaluation program, SCS will have the option to negotiate a commercial licensing agreement that would provide rights to deploy the technology within specified markets and applications. The agreement follows a series of recent commercial-scale evaluations of REV™ technology that delivered encouraging results. According to EnWave, the testing demonstrated that the technology can significantly accelerate drying processes while preserving important product characteristics that are critical for medical and pharmaceutical-grade cannabis products. Independent testing conducted across multiple cannabis cultivars showed no statistically significant differences in sensory quality when compared to conventionally dried products. The evaluations also found no meaningful impact on cannabinoid potency, no material changes in total yeast and mold counts, and generally stable terpene profiles, all of which are key quality metrics within the cannabis industry. One of the most notable findings from the testing was the potential reduction in drying times by approximately two to five days compared to traditional drying methods. Management believes this could create substantial operational benefits, including increased production throughput, improved facility utilization, and reduced dry-room occupancy, ultimately helping producers improve efficiency and lower operating costs. Charleton noted that maintaining product quality while increasing processing speed is becoming increasingly important as the global medical cannabis and cannabinoid-derived pharmaceutical markets continue to expand. The company believes REV™ technology offers a differentiated solution capable of addressing these industry challenges. #proactiveinvestors #enwavecorporation #tsxv #enw #REVTechnology #MedicalCannabis #CannabisTechnology #Pharmaceuticals #REVTechnology #Cannabinoids #Biotech #HealthInnovation #SwissCannabis #ProcessingTechnology